Investor: Medical Company Misled About COVID’s Impact On Drug’s Clinical Testing
RENO, Nev. — A biopharmaceutical company misled investors by failing to disclose that its ability to test a drug planned to treat Alzheimer’s disease was severely impacted by the ongoing COVID-19...To view the full article, register now.
Already a subscriber? Click here to view full article